This month, President Obama unveiled his fiscal 2016 budget, requesting $146 billion in federal funding for R&D. This represents a nominal 6%, or $8 billion, increase over 2015 enacted levels, with inflation expected to rise 1.6%. Most agencies performing R&D would experience budget increases. Of the total, $76.9 billion and $68.8 billion would be for […]
The number of worldwide mergers and acquisitions (M&A) in the chemical industry grew 18.2% to 635 in 2014. The value of the transactions totaled $77.8 billion, an increase of 144.7%. Of the deals announced in 2014, 13 were greater than $1 billion in value, totaling $52 billion. At a value of $40.5 billion, up 181.3%, […]
A new forensics technique, DNA phenotyping, is being employed to assist in creating suspects’ picture profiles, using SNPs associated with differences in appearance. The technique is still in development, and additional research is needed to resolve traits such as facial shape and, with epigenetic information, a suspect’s age. Eye color and hair color can be […]
In 2014, investment in clean energy totaled $310 billion, an increase of 16%, despite the fall in oil prices. Investment in R&D by governments and corporations totaled $14 billion and $15 billion, respectively. Investment in solar- and wind-energy rose 25% and 11% to $149.6 billion and $99.5 billion, respectively. Investment in “energy smart technologies,” such […]
In his fiscal 2016 budget, US President Barack Obama has proposed $215 million to fund the Precision Medicine Initiative. Of the total, $130 million would be for the NIH to gather at least one million volunteer research participants. The National Cancer Institute would receive $70 million to increase its efforts to discover genetic determinants of […]
As oil prices fall, mergers and acquisitions (M&A) in the industry are likely to increase, according to observers. M&A allows for cost cuts and access to new assets, particularly for large oil companies. The first half of 2015 is expected to be slow for oil company M&A as valuations remain uncertain. Nonetheless, two deals that […]
The US Patent and Trademark Office (USPTO) issued new guidance this month on nature-based products. The new document is a revision of a guidance released in March stating that to be eligible for patents, such inventions must be “significantly different” and show structural differences from natural products (see IBO 7/15/14). Feedback from stakeholders claiming that […]
According to the “2014 EU Industrial R&D Investment Scoreboard,” the world’s top 2,500 companies for R&D investment spent €538.5 billion ($718.0 billion) on R&D in fiscal 2013, an increase of 4.9%. Net sales growth for these firms was 2.7%, and their capital spending increased 2.5%. Scoreboard companies each invested more than €15.5 million ($20.7 million) […]
With oil prices at a five-year low, down 20% since July, many oil companies are reducing costs. For example, ConocoPhillips will decrease by 20% its 2015 investment spending, and BP plans cuts to jobs over the next several months. However, ConocoPhillips expects its gas and oil production to increase by over 3% next year due […]
The value of the late-stage pipeline of a cohort of 12 major research-based life science companies has risen for the first time since 2010, growing 5.5% to $966 billion in 2014, versus 5.1% in 2013. Although the number of assets has fallen year over year from 194 to 181, the sales potential of the assets […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
